PATENT CLAIM ANALYSIS

Application Number: 16132150
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-05
Patent Classification: ["424", "133100"]

Abstract:
The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering an anti-CTGF antibody. In particular, the treatment methods provided avoid toxicities associated with approved therapies and also avoid the attenuation of the efficacy of an anti-CTGF antibody caused by these approved therapies.

Claim (Index 13):
A method for improving the quality of life, stabilizing the rate of decline in the quality of life or reducing the rate of decline in the quality of life of a subject having idiopathic pulmonary fibrosis (IPF) comprising, administering an effective dose of an anti-connective tissue growth factor (CTGF) antibody to the subject, thereby improving the quality of life or reducing the rate of decline in the quality of life of the subject.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 97.0
- Lexical Diversity: 1.31707
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16028235', '15263767', '14398380', '14741747', '15852977']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7694729597308271
- 35 USC 102 Novelty (BERT): 0.5611437872916076
- Combined Prediction Score: 0.7486400424869052
- Mean Citation Score: 388.63126
- Max Citation Score: 469.31403
- Similarity Product: 345.8150329916364

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test